(NASDAQ: IPHA) Innate Pharma Sa's forecast annual revenue growth rate of 6.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Innate Pharma Sa's revenue in 2024 is $67,001,086.On average, 2 Wall Street analysts forecast IPHA's revenue for 2024 to be $4,147,411,199, with the lowest IPHA revenue forecast at $1,973,462,405, and the highest IPHA revenue forecast at $6,321,359,993. On average, 2 Wall Street analysts forecast IPHA's revenue for 2025 to be $3,226,301,044, with the lowest IPHA revenue forecast at $2,224,674,266, and the highest IPHA revenue forecast at $4,227,927,821.
In 2026, IPHA is forecast to generate $7,318,960,940 in revenue, with the lowest revenue forecast at $1,829,337,652 and the highest revenue forecast at $12,808,584,228.